Author(s): Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D,
Abstract Share this page
Abstract In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47\% to 61\% with etanercept compared with 11\% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life.
This article was published in J Am Acad Dermatol
and referenced in Journal of Pharmaceutical Care & Health Systems